Lepu Biopharma Announces Promising Results for MRG003 in Pivotal Clinical Trial for Nasopharyngeal Cancer at 2025 ASCO Annual Meeting

Reuters

2025/06/01

Lepu Biopharma Announces Promising Results for MRG003 in Pivotal Clinical Trial for Nasopharyngeal Cancer at 2025 ASCO Annual Meeting

Lepu Biopharma Co. Ltd. has announced the results of a pivotal clinical trial for their drug candidate, MRG003, which were presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The study focused on the treatment of recurrent or metastatic nasopharyngeal cancer (R/M NPC) using MRG003, a novel EGFR-targeted antibody-drug conjugate. In a randomized-controlled, multicenter, open-label study, MRG003 demonstrated statistically and clinically significant benefits in heavily pretreated patients compared to chemotherapy. The trial enrolled 173 patients, with MRG003 showing a higher objective response rate of 30.2% compared to 11.5% for chemotherapy. The study highlights a potential shift in treatment paradigms for R/M NPC. However, the company cautions that there is no guarantee of MRG003's successful development and market launch.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lepu Biopharma Co. Ltd. published the original content used to generate this news brief on June 01, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣0平台費、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣0平台費、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2540397997"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2540397997\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2540397997?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-01 18:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2540397997","market":"nz","top_or_hot":-1,"title":"Lepu Biopharma Announces Promising Results for MRG003 in Pivotal Clinical Trial for Nasopharyngeal Cancer at 2025 ASCO Annual Meeting","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Lepu Biopharma Announces Promising Results for MRG003 in Pivotal Clinical Trial for Nasopharyngeal Cancer at 2025 ASCO Annual Meeting\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Lepu Biopharma Co. Ltd. has announced the results of a pivotal clinical trial for their drug candidate, MRG003, which were presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The study focused on the treatment of recurrent or metastatic nasopharyngeal cancer (R/M NPC) using MRG003, a novel EGFR-targeted antibody-drug conjugate. In a randomized-controlled, multicenter, open-label study, MRG003 demonstrated statistically and clinically significant benefits in heavily pretreated patients compared to chemotherapy. The trial enrolled 173 patients, with MRG003 showing a higher objective response rate of 30.2% compared to 11.5% for chemotherapy. The study highlights a potential shift in treatment paradigms for R/M NPC. However, the company cautions that there is no guarantee of MRG003's successful development and market launch.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lepu Biopharma Co. Ltd. published the original content used to generate this news brief on June 01, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lepu Biopharma Announces Promising Results for MRG003 in Pivotal Clinical Trial for Nasopharyngeal Cancer at 2025 ASCO Annual Meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLepu Biopharma Announces Promising Results for MRG003 in Pivotal Clinical Trial for Nasopharyngeal Cancer at 2025 ASCO Annual Meeting\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-06-01 18:42</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Lepu Biopharma Announces Promising Results for MRG003 in Pivotal Clinical Trial for Nasopharyngeal Cancer at 2025 ASCO Annual Meeting\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Lepu Biopharma Co. Ltd. has announced the results of a pivotal clinical trial for their drug candidate, MRG003, which were presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The study focused on the treatment of recurrent or metastatic nasopharyngeal cancer (R/M NPC) using MRG003, a novel EGFR-targeted antibody-drug conjugate. In a randomized-controlled, multicenter, open-label study, MRG003 demonstrated statistically and clinically significant benefits in heavily pretreated patients compared to chemotherapy. The trial enrolled 173 patients, with MRG003 showing a higher objective response rate of 30.2% compared to 11.5% for chemotherapy. The study highlights a potential shift in treatment paradigms for R/M NPC. However, the company cautions that there is no guarantee of MRG003's successful development and market launch.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lepu Biopharma Co. Ltd. published the original content used to generate this news brief on June 01, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250601:nNDL1GpTSL:1","article_id":"2540397997","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2540397997","pubTimestamp":1748774530,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Lepu Biopharma Announces Promising Results for MRG003 in Pivotal Clinical Trial for Nasopharyngeal Cancer at 2025 ASCO Annual Meeting. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lepu Biopharma Co. Ltd. published the original content used to generate this news brief on June 01, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","02157":"乐普生物-B"},"translate_title":"乐普生物在2025年ASCO年会上宣布MRG003在鼻咽癌关键临床试验中的可喜结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02157":0.9},"content_text":"Lepu Biopharma Announces Promising Results for MRG003 in Pivotal Clinical Trial for Nasopharyngeal Cancer at 2025 ASCO Annual Meeting\n    \n\n        Lepu Biopharma Co. Ltd. has announced the results of a pivotal clinical trial for their drug candidate, MRG003, which were presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The study focused on the treatment of recurrent or metastatic nasopharyngeal cancer (R/M NPC) using MRG003, a novel EGFR-targeted antibody-drug conjugate. In a randomized-controlled, multicenter, open-label study, MRG003 demonstrated statistically and clinically significant benefits in heavily pretreated patients compared to chemotherapy. The trial enrolled 173 patients, with MRG003 showing a higher objective response rate of 30.2% compared to 11.5% for chemotherapy. The study highlights a potential shift in treatment paradigms for R/M NPC. However, the company cautions that there is no guarantee of MRG003's successful development and market launch.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lepu Biopharma Co. Ltd. published the original content used to generate this news brief on June 01, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}